Red Reishi vs. Other Ganoderma Species: Key Differences

Reishi Foundation & Science

93% of 'G. lucidum' kits were a different species

DNA barcoding of 19 commercial reishi products found that 93% of grow-your-own kits labeled 'Ganoderma lucidum' actually contained a different species — Ganoderma sichuanense.

Loyd et al., Frontiers in Microbiology, 2018

180+

described Ganoderma species worldwide

0–7.8%

triterpene content range across 11 commercial US reishi products

ITS

the DNA region used to reliably authenticate Ganoderma species

Loyd et al., Frontiers in Microbiology, 2018

View as image ↗

Walk into any health food store and you will find supplements labeled "Ganoderma lucidum — Reishi." That name is almost certainly wrong. Not because the supplement is fraudulent, but because of a taxonomic tangle that has confused producers and consumers alike for decades: the species that nearly all traditional Chinese medicine and commercial supplements call "reishi" is not, technically, Ganoderma lucidum. It is more likely Ganoderma lingzhi or Ganoderma sichuanense — closely related species that were only formally separated from G. lucidum in modern molecular phylogenetic analysis.

This matters in two ways. First, when you see "Ganoderma lucidum" on a supplement label, you cannot be certain which species you are actually getting. Second, the vast majority of clinical research on reishi was conducted using Asian-grown material that is G. lingzhi, not the true G. lucidum — which is a European species with a narrow native range that rarely enters the commercial supply chain.

For the full science behind what makes reishi pharmacologically active, see What Is Reishi Mushroom? The Science Behind the "Mushroom of Immortality".

The 93% Finding: What DNA Testing Reveals About Reishi Supplements

In 2018, Loyd and colleagues published the most rigorous commercial authentication study of reishi products to date.^[1] Using DNA barcoding, they analyzed 19 commercial reishi products including grow-your-own kits and dried mushroom products, all of which were labeled as containing Ganoderma lucidum.

The results were striking: 93% of the grow-your-own kits contained Ganoderma sichuanense rather than the species advertised. Among dried products, 50% contained G. sichuanense rather than G. lucidum.

What Loyd found was not a fraud problem in the traditional sense. The mushrooms were genuinely from the reishi group — they were authentic functional fungi with the general characteristics associated with Asian reishi. The issue was taxonomic precision: species that had long been lumped together under the "G. lucidum" umbrella had been formally separated by molecular phylogenetics, and the commercial supply chain had not caught up.

The implication for consumers is not necessarily that the products are ineffective. G. lingzhi and G. sichuanense are the species behind most of the clinical research on reishi — so products containing these species may be doing exactly what the research suggests. The implication is rather that "Ganoderma lucidum" as a label tells you almost nothing reliable about which species you have, which matters when you are trying to match a product to specific research.

Gunnels and colleagues, in a 2020 study published in PLoS ONE, validated the ITS (internal transcribed spacer) region of ribosomal DNA as the gold-standard molecular marker for distinguishing Ganoderma species in commercial preparations.^[2] ITS barcoding works by comparing a short, species-specific DNA sequence extracted from the mushroom material against a reference database. This is the same approach used to verify species identity in pharmaceutical-grade botanical ingredients and is now the standard method for academic authentication studies.

G. lucidum vs. G. lingzhi vs. G. sichuanense: What's Actually Different

To understand why there is so much confusion, you need to know a little about the history of Ganoderma taxonomy.

The name "Ganoderma lucidum" was first applied by European mycologists in the 19th century to a species found in Europe, particularly around the Mediterranean. This European G. lucidum is real and correctly named — it is a polypore bracket fungus with a characteristic lacquered red cap, kidney-shaped form, and woody texture. But its native range is primarily temperate Europe. It is not the species that has been used in Chinese and Japanese traditional medicine for 2,000 years.

The Asian medicinal species — the one behind virtually all of the pharmacological research, all of the traditional use, and most of the commercial supply — was long assumed to be the same G. lucidum. Molecular phylogenetic analysis, which became practical in the 2000s, revealed that Asian reishi and European G. lucidum are genetically distinct. The Asian species was formally designated G. lingzhi (lingzhi being the Chinese name for this mushroom) and G. sichuanense (named for Sichuan province, where it is particularly common).

The practical consequence: when a study on reishi refers to "Ganoderma lucidum," it almost certainly used material that is actually G. lingzhi or G. sichuanense. This is not methodological error — the researchers were working with the correct medicinal material. It is a naming lag, and it means the entire body of "G. lucidum" research applies most accurately to G. lingzhi and G. sichuanense, not to the true European G. lucidum.

How the primary species in commercial reishi products compare:

For a deeper look at how to identify authentic reishi material and what authentication methods show, see Ganoderma lucidum Taxonomy: How to Identify Authentic Reishi Species.

Why the Naming Confusion Has a Real-World Impact

Species mislabeling would be a minor academic concern if all members of the G. lucidum species complex produced identical bioactive compounds in identical concentrations. They do not.

Wu and colleagues analyzed 11 commercial Ganoderma lucidum dietary supplements collected from US retailers in 2017.^[3] Triterpene content varied from undetectable levels to 7.8% across products. Polysaccharide content ranged from 1.1% to 5.8%. This is not random manufacturing variation — it reflects genuine differences in source material, species, cultivation conditions, and extraction methods.

Different Ganoderma species have different triterpene profiles even within the species complex. The specific ganoderic acids (the primary pharmacologically active triterpenes in reishi) vary in concentration and type across species and growing conditions. A supplement made from G. sichuanense grown on sawdust substrate in a controlled facility will have a different compound profile than one made from G. lingzhi grown on oak logs in China.

This compound variation is what makes species authentication more than a labeling nicety. If the clinical research demonstrating reishi's effects used G. lingzhi at specific triterpene concentrations, a product with undetectable triterpenes — regardless of what species name appears on the label — would not be expected to reproduce those effects.

For more on how compound content varies and what extraction methods capture, see Reishi Bioactive Compounds: Triterpenes, Polysaccharides, and Sterols.

Hemlock Reishi: What Makes G. tsugae Different

Ganoderma tsugae deserves specific attention because it is genuinely different from the Asian medicinal species in one important way: its host tree.

G. tsugae grows exclusively or primarily on hemlock trees (Tsuga species), which are conifers. The Asian medicinal species — G. lingzhi and G. sichuanense — grow on deciduous hardwood trees including oak, plum, and Chinese maple. Host tree species significantly affects the chemical composition of fungal fruiting bodies, because the fungus metabolizes compounds from its host substrate as part of its growth.

G. tsugae has been studied and does contain ganoderic acids and beta-glucans. Some research has found similar general activities to G. lingzhi. However, the depth of research on G. tsugae is substantially less than on G. lingzhi, and the compound profiles are not identical. When products market "North American reishi," they are typically referring to G. tsugae, and buyers should be aware that this is a distinct species from the one behind most clinical research.

G. tsugae is genuinely a member of the medicinal Ganoderma group. It is not the same as G. applanatum or other non-medicinal species. But "similar general activities" in limited research is not the same as the clinical evidence base that exists for Asian G. lingzhi.

The Impostors: Species That Aren't Medicinal Ganoderma

Two species are particularly worth knowing because they look enough like medicinal reishi to cause confusion, but lack the supporting research and compound profiles.

Ganoderma applanatum, commonly known as artist's conk, is widespread across the Northern Hemisphere and grows on a variety of deciduous trees. It is a bracket fungus — shelf-like, attached to tree trunks — and shares the same genus as medicinal reishi. But it lacks the lacquered, varnished appearance of G. lingzhi and has a flat, woody, grey-brown upper surface rather than the characteristic shiny red cap. More importantly, G. applanatum has not been established as a medicinal species with equivalent triterpene and beta-glucan profiles. Its presence in the same genus does not make it pharmacologically equivalent to G. lingzhi.

Ganoderma oregonense is a North American species found primarily on fir and pine trees in the Pacific Northwest. It is physically larger than G. lingzhi and lacks the same compound profile. It is not documented as a medicinal species in the research literature and should not be used as a substitute for G. lingzhi-based products.

The practical risk: wild-harvested "reishi" from North American suppliers may include G. tsugae (has some research basis), G. oregonense (no research basis), or G. applanatum (no medicinal profile), depending on local geography and harvesting practices. None of these are fraudulent in the sense of being harmful — but buyers expecting the pharmacological profile of G. lingzhi are not getting it from G. applanatum or G. oregonense.

The Medicinal Landscape: Where Reishi Fits Against Other Mushrooms

Guggenheim and colleagues, in a 2014 comparative review of five major medicinal mushrooms in Integrative Medicine, positioned Ganoderma's beta-glucans and triterpenes within the broader landscape of medicinal fungi.^[4] The review covered reishi alongside turkey tail, shiitake, maitake, and chaga — and found that Ganoderma's triterpene profile is genuinely distinctive within this group. Turkey tail, shiitake, and maitake are primarily studied for their polysaccharide content, while reishi is the only major medicinal mushroom species with a well-characterized high-triterpene profile alongside its polysaccharides.

Lysakowska and colleagues, in a 2023 comparative review published in Molecules, confirmed this positioning: across medicinal mushroom species, Ganoderma stands out for the diversity and concentration of its triterpene compounds.^[5] No other major medicinal mushroom species approaches the 120+ characterized triterpene compounds found in Ganoderma.

This distinction matters for the species question: it is specifically the triterpene diversity that makes species identity important. A product containing a Ganoderma species with a different triterpene profile — whether because of genuine species substitution or because the claimed G. lucidum is actually G. sichuanense from a low-quality source — may not deliver the full compound range that distinguishes reishi from other medicinal mushrooms.

For how reishi compares to other functional mushrooms in immune and anti-inflammatory activity specifically, see The Pharmacology of Ganoderma lucidum: How Reishi Works.

How to Verify What You're Actually Getting

The Gunnels 2020 ITS barcoding study established the scientific standard for species verification, but most consumers cannot send mushroom samples to a molecular biology lab.^[2] There are practical approaches that provide meaningful verification short of DNA testing.

The most useful label information for species verification:

Genus and species with clarity. A label that says "Ganoderma lingzhi" or "Ganoderma sichuanense" is more informative than one that says "Ganoderma lucidum" — the former acknowledges the current taxonomic understanding, while the latter is almost certainly a naming lag. Some high-quality producers now use G. lingzhi or add a note about species complex. This is a positive signal.

Certificate of Analysis with compound data. A supplement that provides verified triterpene content (expressed as a percentage, typically 1–7%) and beta-glucan content (typically 15–30% for quality fruiting body products) gives you more meaningful information than a species name alone. Wu et al.'s finding of 0–7.8% triterpene range across commercial products reflects real product-to-product variation — a COA pins down where a specific product falls.

Fruiting body vs. mycelium source. This is a separate but related quality question. The authenticated Ganoderma species distinction applies to fruiting bodies. Mycelium-on-grain products have a different compound profile regardless of species, and the species name on a mycelium product is less predictive of its active compound content.

ITS testing availability. A small number of brands now offer or mention ITS species verification. Gunnels 2020 validated this method — if a brand references ITS testing or uses the validated G. lingzhi or G. sichuanense designation, that indicates awareness of the authentication question.

For a full breakdown of how to verify mushroom supplement quality, including COA interpretation and DNA testing, see DNA Testing for Mushroom Supplements: Verifying Species Identity. For the fruiting body vs. mycelium question specifically, see Do Fruiting Bodies Have More Bioactive Compounds Than Mycelium?.

The Bottom Line

The "Ganoderma lucidum" label on most commercial reishi products is almost certainly taxonomically incorrect. DNA barcoding shows that 93% of grow-your-own kits and 50% of dried products labeled G. lucidum contain Ganoderma sichuanense, a closely related Asian species. The true G. lucidum is European with a narrow native range and is rarely in the commercial supply chain. This matters because different Ganoderma species have different triterpene profiles, and the clinical research on reishi was conducted with G. lingzhi and G. sichuanense — not the true G. lucidum. Species outside the medicinal complex (G. applanatum, G. oregonense) lack the research basis of G. lingzhi entirely. Verification via ITS barcoding or Certificate of Analysis with triterpene content provides more meaningful quality information than the species name on a label.

Frequently Asked Questions

What is the difference between Ganoderma lucidum and Ganoderma lingzhi?

Ganoderma lucidum (sensu stricto) is a European species with a Mediterranean native range. Ganoderma lingzhi is the primary Asian medicinal species used in traditional Chinese medicine and most clinical research. They were long treated as the same species but molecular analysis shows they are genetically distinct. The name G. lucidum is still commonly used on supplements to refer to G. lingzhi material — but the two are taxonomically different species with potentially different compound profiles.

What species is actually sold as reishi in supplements?

DNA testing of commercial reishi products shows that most contain Ganoderma sichuanense or G. lingzhi, not the true G. lucidum. A 2018 study of 19 commercial products found 93% of grow-your-own kits and 50% of dried products labeled G. lucidum actually contained G. sichuanense. This is not necessarily a problem — G. lingzhi and G. sichuanense are the species behind most clinical research. But the G. lucidum label tells you little about which species you actually have.

Are all Ganoderma species equally medicinal?

No. G. lingzhi and G. sichuanense have the strongest research basis, built from thousands of studies using Asian-sourced material. G. tsugae (hemlock reishi) has some supporting research. G. applanatum (artist's conk) and G. oregonense (western varnish shelf) are in the same genus but have no comparable medicinal research base and lack the characteristic triterpene profiles of the medicinal species. The genus name alone does not predict pharmacological activity.

Is Ganoderma tsugae the same as reishi?

G. tsugae is a related species sometimes called hemlock reishi because it grows on hemlock trees. It is in the same genus as G. lingzhi and does contain ganoderic acids and beta-glucans. Some research has found similar general activities to G. lingzhi. However, G. tsugae has substantially less research behind it than G. lingzhi, its compound profile differs because of its conifer host tree, and it should not be treated as interchangeable with the Asian medicinal species that backs most clinical evidence.

What is Ganoderma sichuanense?

G. sichuanense is a species in the Ganoderma lucidum species complex, named for Sichuan province in China where it is commonly found. It is genetically distinct from the true G. lucidum (European) and closely related to G. lingzhi. DNA barcoding studies show it is the species most commonly found in products labeled "G. lucidum" in commercial markets. It is a legitimate medicinal species — most of the Asian reishi research applies to it — but it is different from what the European G. lucidum designation technically refers to.

What is the difference between red, black, and purple reishi?

In traditional Chinese medicine, six types of lingzhi were described by color: red, black, white, yellow, blue/green, and purple. These color designations were based on appearance and did not correspond to modern species classifications. Modern DNA analysis does not consistently separate these color variants into distinct species with different pharmacological profiles. The "red reishi" marketed in supplements is typically G. lingzhi or G. sichuanense and represents the species with the strongest research base. Black and purple designations are not standardized in the scientific literature.

Is hemlock reishi as good as red reishi?

Not equivalently supported by research. G. tsugae (hemlock reishi) is a related medicinal species with some research behind it, but the depth and breadth of evidence for G. lingzhi (the primary "red reishi" species) is substantially greater. G. tsugae also has a different compound profile reflecting its conifer host tree. For buyers seeking the compound profile and evidence base of traditional Asian reishi, G. lingzhi or G. sichuanense is the species with the most direct research support.

Sources & References

1. 1RTHM-00981·Loyd, Andrew L et al. (2018). “Identifying the "Mushroom of Immortality": Assessing the Ganoderma Species Composition in Commercial Reishi Products..” Frontiers in microbiology.Study breakdown →PubMed →↩
2. 2RTHM-00615·Gunnels, Tess et al. (2020). “The ITS region provides a reliable DNA barcode for identifying reishi/lingzhi (Ganoderma) from herbal supplements..” PloS one.Study breakdown →PubMed →↩
3. 3RTHM-00499·Wu, Ding-Tao et al. (2017). “Evaluation on quality consistency of Ganoderma lucidum dietary supplements collected in the United States..” Scientific reports.Study breakdown →PubMed →↩
4. 4RTHM-00323·Guggenheim, Alena G et al. (2014). “Immune Modulation From Five Major Mushrooms: Application to Integrative Oncology..” Integrative medicine (Encinitas.Study breakdown →PubMed →↩
5. 5RTHM-00843·Łysakowska, Paulina et al. (2023). “Medicinal Mushrooms: Their Bioactive Components, Nutritional Value and Application in Functional Food Production-A Review..” Molecules (Basel.Study breakdown →PubMed →↩